Exact Sciences Announces Cologuard Will Now Be Available By Prescription Through MDVIP Physicians

BOCA RATON, Fla. & MADISON, Wis.--(BUSINESS WIRE)-- MDVIP, the leader in personalized preventive medicine with a nationwide network of over 750 affiliated primary care physicians, announced today that Cologuard®, the first and only Food and Drug Administration (FDA) approved, noninvasive stool DNA screening test for colorectal cancer will now be available by prescription through its physicians. MDVIP is the first personalized healthcare network to partner with Exact Sciences to bring this innovative new test to its primary care physicians.

"MDVIP physicians have traditionally been early adopters of medical innovation," says Dr. Andrea Klemes, Chief Medical Officer of MDVIP. "Cologuard, a significant advancement in colorectal cancer detection, will allow our patients who are 50 years and older and at average risk for colorectal cancer, an easy to use screening test which they can do in the privacy of their own home."

Read More

Topics: Exact Sciences News

Exact Sciences Announces Mayo Clinic as First Healthcare System to Offer Cologuard®

Stool-based DNA (sDNA) screening test for colorectal cancer to be available by prescription to patients

MADISON, Wis. & ROCHESTER, Minn.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ:EXAS) today announced that Mayo Clinic will be the first health system to offer Cologuard®, the first and only Food and Drug Administration (FDA) approved, noninvasive stool DNA screening test for colorectal cancer. Cologuard will be available to patients through their primary care physicians at Mayo Clinic.

Read More

Topics: Exact Sciences News

FDA Approves Exact Sciences’ Cologuard®; First and Only Stool DNA Noninvasive Colorectal Cancer Screening Test

Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.

Read More

Topics: Exact Sciences News

Exact Sciences Announces FDA Advisory Committee Unanimously Recommends Approval of Cologuard

MADISON, WI. – Exact Sciences Corp. (NASDAQ: EXAS) today announced that the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee determined by a unanimous vote of 10 to zero that Exact Sciences has demonstrated safety, effectiveness and a favorable risk benefit profile of Cologuard ®, the company's stool-based DNA (sDNA), non-invasive colorectal cancer screening test.

Read More

Exact Sciences’ DeeP-C Study Results Published in New England Journal of Medicine

Non-invasive, Stool-based DNA Test Shown to Detect 92% of People with Colorectal Cancer compared to 74% for the Fecal Immunochemical Test (FIT)

MADISON, WI. – Exact Sciences Corp. (Nasdaq: EXAS) today announced that results from its DeeP-C pivotal clinical study have been published online in the New England Journal of Medicine. The peer-reviewed study, “Multi-target Stool DNA Testing for Colorectal-Cancer Screening” will also appear in the journal’s April 3, 2014 print issue.

Read More

DeeP-C Clinical Trial Preliminary Top-Line Results

Top-line data show Exact Sciences’ Cologuard test demonstrates 92 percent sensitivity in the detection of colorectal cancer

All endpoints achieved in 10,000-patient trial of non-invasive, convenient DNA-based screening test for colorectal cancer and pre-cancerous polyps

MADISON, WI. – Exact Sciences Corp. (Nasdaq: EXAS) today announced that preliminary analysis shows that the company’s Cologuard colorectal cancer screening test met or exceeded all primary and secondary endpoints of its recently completed DeeP-C pivotal clinical trial. The clinical trial evaluated the test’s use for the detection of colorectal cancer and pre-cancerous polyps.

Read More

Exact Sciences Receives AMGA Distinguished Corporate Partner Award

ORLANDO, FL. – The American Medical Group Association (AMGA) announced today that it will present the AMGA Distinguished Corporate Partner Award on March 15 to Exact Sciences at its 2013 Annual Conference, March 14-16 at the Hilton Bonnet Creek Resort in Orlando.

The AMGA Distinguished Corporate Partner Award is presented annually to a non-medical group organization for providing excellent service and value to medical groups and their patients.

Read More

Exact Sciences Completes Enrollment of DeeP-C Clinical Trial for Colorectal Cancer Screening

More than 12,700 patients enrolled to evaluate the company’s non-invasive stool-based DNA test to detect the second leading cause of cancer deaths.

MADISON, WI. – Exact Sciences Corp. (Nasdaq: EXAS) today announced it has completed patient enrollment in its DeeP-C pivotal trial for colorectal cancer screening. The study enrolled more than 12,700 patients at sites in the United States and Canada.

Read More